ライフサイエンスコーパス: adverse cardiac event

1 rdial infarction, and their composite, major adverse cardiac events).

2 mortality) into a composite end point (major adverse cardiac events).

3 The primary safety end point was a major adverse cardiac event.

4 s, 2183 (23.9%) patients experienced a major adverse cardiac event.

5 se events, serious adverse events, and major adverse cardiac event.

6 iomyopathy/dysplasia and a high incidence of adverse cardiac events.

7 owed for 30 days for the occurrence of major adverse cardiac events.

8 improved prediction of 1-year death or major adverse cardiac events.

9 diac troponin T with the occurrence of major adverse cardiac events.

10 ssociated with increased risk of in-hospital adverse cardiac events.

11 y periprocedural mortality and rate of major adverse cardiac events.

12 int of the study was the occurrence of major adverse cardiac events.

13 ntly associated with the occurrence of major adverse cardiac events.

14 CMR was significantly associated with major adverse cardiac events.

15 int of the study was the occurrence of major adverse cardiac events.

16 clinical risk score for prediction of major adverse cardiac events.

17 independent predictor of mortality and major adverse cardiac events.

18 dial infarction, stent thrombosis, and major adverse cardiac events.

19 tacted patients by telephone to assess major adverse cardiac events.

20 riven unplanned revascularization, and major adverse cardiac events.

21 ives included platelet aggregation and major adverse cardiac events.

22 hose who will have a high long-term risk for adverse cardiac events.

23 ctive chart review was performed to identify adverse cardiac events.

24 n alone at reducing short or long-term major adverse cardiac events.

25 have coronary artery disease (CAD) or future adverse cardiac events.

26 ment of SVGs with embolic protection reduces adverse cardiac events.

27 with respect to the rate of subsequent major adverse cardiac events.

28 dependent prognostic imaging marker of major adverse cardiac events.

29 y intervention in reducing the risk of major adverse cardiac events.

30 inary in-stent restenosis and 12-month major adverse cardiac events.

31 , target lesion revascularization, and major adverse cardiac events.

32 th negative test results go on to experience adverse cardiac events.

33 anges in LV volumes, infarct size, and major adverse cardiac events.

34 There was no difference in major adverse cardiac events (1.8% versus 2.3%; P=0.75) at 30

35 Mortality (0% vs. 1.9%, p = 0.06) and major adverse cardiac events (1.8% vs. 2.3%, p = 0.75) at 30 d

36 % versus 19.12%; P=0.078) and 12-month major adverse cardiac events (10.29% versus 19.12%; P=0.213) w

37 y rate (9.3% versus 20.1%; P<0.01) and major adverse cardiac events (13.0% versus 26.4%; P<0.01) but

38 [3.4%] vs 29 of 365 [7.9%]; P = .007), major adverse cardiac events (15 of 382 [3.9%] vs 30 of 365 [8

39 te group, and 4% in the vilanterol group) or adverse cardiac events (17% in the placebo group, 18% in

40 tality (8 [7.7%] versus 12 [1.9%]) and major adverse cardiac events (21 [20.2%] versus 31 [4.9%]) rat

41 follow-up, there was no difference for major adverse cardiac events (25.3 versus 25.4%; P=0.683); all

42 0.36-1.00; P = .046); and for overall major adverse cardiac events, 39 (20.1%) vs 22 (11.5%) (RR, 0.

43 9%]) and a 1.21-fold increased risk of major adverse cardiac events (4.24% vs 3.50%; absolute increas

44 confidence interval: 0.46 to 1.66) and major adverse cardiac events (4.8% vs. 5.5%; adjusted hazard r

45 oing stress-CMR showed a lower rate of major adverse cardiac events (5% versus 10%; P<0.010) and cost

46 ciated with a reduction in the risk of major adverse cardiac events (6.5% versus 10.3%; odds ratio, 0

47 2%, and 0.7%, p < 0.001), and rates of major adverse cardiac events (8%, 5%, 3%, and 4%, p = 0.052) d

48 dence interval [CI], 1.32-3.18) and of major adverse cardiac events (88/681 events [13.6%] in RR192 a

49 At 2 years, there was no difference in major adverse cardiac events (98.0% for ETT and 97.7% for MPI;

50 use death, all-cause readmissions, and major adverse cardiac events (a composite of all-cause death o

51 The primary end point was major adverse cardiac events, a composite of cardiac death, my

52 Primary end point was the rate of major adverse cardiac events, a composite of cardiac death, ta

53 terms of major adverse cardiac events (major adverse cardiac events, a composite of death, myocardial

54 coprimary end points were the rates of major adverse cardiac events--a composite of death, myocardial

55 mary end point was the occurrence of a major adverse cardiac event: a composite of death, reinfarctio

56 ssociated with a higher 2-year risk of major adverse cardiac events (adjusted hazard ratio, 2.34; 95%

57 n between HPR and SVG PCI in regard to major adverse cardiac events (adjusted Pinteraction=0.99).

58 months, 14 patients (7.6%) suffered a major adverse cardiac event after sevoflurane and 17 (8.5%) af

59 Patients were evaluated for adverse cardiac events after cardiac magnetic resonance

60 There were no major adverse cardiac events after discharge in either group.

61 The cumulative risk of major adverse cardiac events after maximum follow-up was highe

62 nostic strategies had no difference in major adverse cardiac events after normal index testing (0.8%

63 total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78)

64 total mortality or hospitalization for major adverse cardiac events (aHR: 2.02; 95% CI: 1.32 to 3.07)

65 rs to determine medication history and major adverse cardiac events: all-cause mortality, nonfatal my

66 ate, an abnormal MPI failed to predict major adverse cardiac events, although it was associated with

67 he incremental risk of noncardiac surgery on adverse cardiac events among post-stent patients is high

68 </=1, nitrite reduced infarct size and major adverse cardiac event and improved myocardial salvage in

69 red with the prestent era, in-hospital major adverse cardiac events and 1-year target vessel revascul

70 OPCAB is associated with fewer major adverse cardiac events and benefits women disproportiona

71 0001) with low negative event rates of major adverse cardiac events and cardiac death (0.6% and 0.4%,

72 erienced significantly higher rates of major adverse cardiac events and coronary revascularization th

73 increased short-term and long-term risk for adverse cardiac events and mortality.

74 and heart rate (HR) increasing the risk for adverse cardiac events and stroke during physical activi

75 ks of 30-day all-cause readmissions or major adverse cardiac events, and 1-year mortality, all-cause

76 evaluated mortality, 7 (30%) evaluated major adverse cardiac events, and 2 (9%) evaluated angiographi

77 ostoperative NT-proBNP concentrations, major adverse cardiac events, and delirium.

78 ailure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers.

79 CMR has a high negative predictive value for adverse cardiac events, and the absence of inducible per

80 on myocardial infarction patients with major adverse cardiac events as compared with those without (2

81 Importantly, the risk for major adverse cardiac events associated with FFR/CFVR discorda

82 (P=0.05) and reduction in [corrected] major adverse cardiac event at 1 year (2.6% versus 15.8%; P=0.

83 ear (HR, 1.24; 95% CI, 1.14-1.36), and major adverse cardiac events at 1 year (HR, 1.21; 95% CI, 1.12

84 ed in a lower rate of the composite of major adverse cardiac events at 1 year among patients with STE

85 Major adverse cardiac events at 1 year occurred in 13.2% of th

86 Major adverse cardiac events at 1 year occurred in 24 patients

87 Major adverse cardiac events at 1 year were higher with the MG

88 The primary endpoint was major adverse cardiac events at 1 year, and the data for the 5

89 er in postoperative NT-proBNP release, major adverse cardiac events at 1 year, or delirium.

90 mbus was independently associated with major adverse cardiac events at 1-year follow-up.

91 ently associated with the incidence of major adverse cardiac events at 12 months (hazard ratio, 2.73;

92 n strategy with respect to the rate of major adverse cardiac events at 12 months.

93 Major adverse cardiac events at 3 years were significantly low

94 6 weeks and 1.8 percentage points for major adverse cardiac events at 9 months.

95 th respect to mortality at 6 weeks and major adverse cardiac events at 9 months.

96 s abciximab and found similar rates of major adverse cardiac events at 90 days with significantly les

97 er volume was associated with improved major adverse cardiac events at every threshold, regardless of

98 mine whether the 1-year differences in major adverse cardiac event between a stent eluting biolimus f

99 d curves for target vessel failure and major adverse cardiac events between 1 and 2 years evident.

100 No difference was observed in major adverse cardiac events between sexes and ED strategies (

101 The adjusted hazard ratios for major adverse cardiac events between the highest and lowest PO

102 in significant reductions in composite major adverse cardiac events both at 9 months (4.6% vs 8.1%; r

103 noncardiac surgery contribute to the risk of adverse cardiac events, but the relative contributions o

104 mortality, all-cause readmissions, or major adverse cardiac events, but these were attenuated after

105 The most common cause for adverse cardiac events by antidepressants is acquired lo

106 ry disease) improved discrimination of major adverse cardiac events (C statistic, 0.81-0.86; P=0.04;

107 o 0.98; P=0.04) and a 45% reduction in major adverse cardiac events (cardiac death, myocardial infarc

108 secondary end point was evaluation of major adverse cardiac events (cardiac death, myocardial infarc

109 with increased risk for postdischarge major adverse cardiac events (cardiac death, myocardial infarc

110 The primary outcome was major adverse cardiac events (cardiac death, recurrent myocard

111 erformed to document the occurrence of major adverse cardiac events: cardiac death, myocardial infarc

112 medical history and the occurrence of major adverse cardiac events (cardiovascular death, myocardial

113 target lesion revascularization), and major adverse cardiac events (combination of all-cause death,

114 Endpoints were major adverse cardiac events (composite of death, reinfarction

115 mortality, myocardial infarction, and major adverse cardiac events (comprising mortality, myocardial

116 Major adverse cardiac events could be predicted using a seven-

117 Estimated 10-year rate of major adverse cardiac events (death, heart failure, myocardial

118 entations had an independent effect on major adverse cardiac events (death, MI, and re-target lesion

119 y outcome was 1-year composite rate of major adverse cardiac events (death, myocardial infarction, or

120 x length of stay, early discharge, and major adverse cardiac events (death, myocardial infarction, or

121 Postoperative adverse cardiac events decrease as the time from stent p

122 The primary end point was major adverse cardiac events defined as all-cause mortality, h

123 , cumulative effective radiation dose, major adverse cardiac events, defined as a composite end point

124 mary end point was 2-year incidence of major adverse cardiac events, defined as CAD death or hospital

125 g in a significant reduction in 1-year major adverse cardiac events, driven by a lower incidence of t

126 es of target vessel failure, and fewer major adverse cardiac events during 1 year of follow-up.

127 ssful procedure without device-related major adverse cardiac events during 6 months.

128 (ACS) during index hospitalization and major adverse cardiac events during 6-month follow-up.

129 The rate of major adverse cardiac events during a median follow-up of 12.1

130 ationic protein serum levels predicted major adverse cardiac events during follow-up (odds ratio =1.0

131 dure and hospitalization and costs for major adverse cardiac events during follow-up.

132 death, myocardial infarction (MI), and major adverse cardiac events during the follow-up period (medi

133 To assess the rates of major adverse cardiac events during the index admission and 1

134 linked to approximately 19% incidence of an adverse cardiac event (e.g., heart failure, arrhythmia,

135 Adverse cardiac events followed surgery in 531 (5.7%) of

136 resulted in a significant decrease of major adverse cardiac events for up to 2 years after the index

137 BG and 2255 PCI patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated

138 herapy as a more powerful predictor of major adverse cardiac event-free survival than choice of thera

139 adherent patients, CABG affords better major adverse cardiac event-free survival.

140 as a powerful incremental predictor of major adverse cardiac events (hazard ratio, 0.80 [95% confiden

141 ndiabetic patients had higher risks of major adverse cardiac events (hazard ratio, 1.25; 95% confiden

142 was an independent predictor of 1-year major adverse cardiac events (hazard ratio, 1.36; 95% confiden

143 a significant independent predictor of major adverse cardiac events (hazard ratio, 4.41 [confidence i

144 ent predictor of lower rates of 30-day major adverse cardiac events (hazard ratio: 0.72 [95% confiden

145 demonstrated a strong association with major adverse cardiac events (hazard ratio=14.66; P<0.0001) wi

146 cally significant predictor of time to major adverse cardiac events (hazard-ratio, 3.36; 95% confiden

147 ciated with higher incidence of 1-year major adverse cardiac event (hazards ratio=2.2; P=0.02).

148 8; P=0.004), and composite adjudicated major adverse cardiac events (ie, cardiac death, myocardial in

149 ity, cardiac events, and the composite major adverse cardiac events (ie, death, acute myocardial infa

150 re are no published data on short-term major adverse cardiac events in hospitalized patients undergoi

151 dependently associated with 30-day death and adverse cardiac events in patients 65 years or older und

152 <39%) on postoperative 30-day mortality and adverse cardiac events in patients 65 years or older und

153 hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolong

154 ngs on positron emission tomography (PET) to adverse cardiac events in patients referred for evaluati

155 Eptifibatide reduces major adverse cardiac events in patients with acute coronary s

156 We sought to assess the predictors of adverse cardiac events in patients with acute coronary s

157 nostic value of stress CMR for prediction of adverse cardiac events in patients with known or suspect

158 re and safety, defined as freedom from major adverse cardiac events in patients with normal index tes

159 h results from carbamylation, predicts major adverse cardiac events in patients with normal renal fun

160 Risks of SCAD recurrence and major adverse cardiac events in the long term emphasize the ne

161 It found a 17% overall reduction in major adverse cardiac events in the statin-treated group compa

162 Major adverse cardiac events included death, myocardial infarc

163 evels in blood predict future risk for major adverse cardiac events including myocardial infarction,

164 The risk of experiencing an adverse cardiac event, including syncope, aborted cardia

165 We assessed major adverse cardiac events, including cardiac death, myocard

166 Major adverse cardiac events, including cardiac death, nonfata

167 entified a subgroup with a very low risk for adverse cardiac events, including ventricular arrhythmia

168 Mortality and major adverse cardiac events increase as operator volumes decr

169 ath or nonfatal myocardial infarction (major adverse cardiac events) incremental to clinical risk mod

170 atification through (1) its association with adverse cardiac events independent of clinical factors a

171 ysis inhibitor, and lipoprotein(a) for major adverse cardiac events is highly variable and conflictin

172 c mismatch or whether mismatch is related to adverse cardiac events is unknown.

173 Recently, major adverse cardiac event (MACE) and mortality risk calculat

174 his study recorded the occurrence of a major adverse cardiac event (MACE) assessed as the composite o

175 hospitalization (primary outcome) or a major adverse cardiac event (MACE) or death within 30 days (se

176 P-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type

177 The primary endpoint was a major adverse cardiac event (MACE) within 30 days.

178 The primary endpoint was major adverse cardiac event (MACE) within 30 days.

179 ation were followed for instances of a major adverse cardiac event (MACE), such as a myocardial infar

180 cardiac tumour formation on MRI, or a major adverse cardiac event (MACE; composite of death and hosp

181 oke, myocardial infarction or combined major adverse cardiac events (MACE = death or stroke or myocar

182 Secondary outcomes included major adverse cardiac events (MACE) (any of the 3 primary end

183 primary endpoint was the composite of major adverse cardiac events (MACE) (cardiovascular death, myo

184 re estimates for revascularization and major adverse cardiac events (MACE) (death, myocardial infarct

185 Endpoints were adjudicated major adverse cardiac events (MACE) (death, myocardial infarct

186 idence interval [CI]: 0.74 to 1.34) or major adverse cardiac events (MACE) (death, readmission for my

187 gender and sex with recurrent ACS and major adverse cardiac events (MACE) (e.g., ACS, cardiac mortal

188 onal primary PCI (18 trials, n=3,936): Major adverse cardiac events (MACE) (risk ratio [RR]: 0.76; 95

189 were cardiac death, general mortality, major adverse cardiac events (MACE) (severe angina, myocardial

190 timing of surgery and stent type with major adverse cardiac events (MACE) adjusting for patient, sur

191 and built the best overall models for major adverse cardiac events (MACE) and cardiac mortality.

192 ended algorithm) for predicting 30-day major adverse cardiac events (MACE) and to compare it with the

193 Primary endpoint was major adverse cardiac events (MACE) at 1 year consisting of ca

194 The ability of each score to predict major adverse cardiac events (MACE) at 1 year was compared.

195 ts, platelet function, and the risk of major adverse cardiac events (MACE) at 2 years was assessed in

196 imary effectiveness outcome was 2-year major adverse cardiac events (MACE) comprising death, readmiss

197 All patients were followed up for major adverse cardiac events (MACE) defined as a composite end

198 nd the combined endpoints (n = 116) of major adverse cardiac events (MACE) defined as cardiovascular

199 with pneumococcal pneumonia experience major adverse cardiac events (MACE) during or after pneumonia.

200 and validity of composite end points, major adverse cardiac events (MACE) in particular, in cardiolo

201 great potential for the prediction of major adverse cardiac events (MACE) in ST-segment-elevation my

202 he primary endpoint was a composite of major adverse cardiac events (MACE) including cardiac death, n

203 At one year, major adverse cardiac events (MACE) occurred in 13.5% of TAXUS

204 etermine the annualized probability of major adverse cardiac events (MACE) of cardiac death or myocar

205 efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days.

206 Major adverse cardiac events (MACE) were assessed in the 2 pro

207 Major adverse cardiac events (MACE) were defined as death, non

208 rvention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days.

209 Major adverse cardiac events (MACE), comprising significant no

210 Primary end point was 8-month major adverse cardiac events (MACE), defined as adjudicated de

211 We recorded the occurrence of major adverse cardiac events (MACE), defined as deaths from al

212 TMP) blush, ST-segment resolution, and major adverse cardiac events (MACE), defined as the occurrence

213 hospital and 30-day) and late (1-year) major adverse cardiac events (MACE), including cardiac death,

214 Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac death,

215 Major bleeding and major adverse cardiac events (MACE), including death, myocardi

216 The primary end point was 1-year major adverse cardiac events (MACE), which included death/myoc

217 verolimus-eluting stents) for reducing major adverse cardiac events (MACE).

218 mportant risk factor for postoperative major adverse cardiac events (MACE).

219 ortality, cardiovascular mortality and major adverse cardiac events (MACE).

220 oints were in-stent binary restenosis, major adverse cardiac events (MACE: cardiac death, myocardial

221 Secondary end points were major adverse cardiac events (MACE; a composite of all-cause d

222 Secondary efficacy end points included major adverse cardiac events (MACE; cardiac death, myocardial

223 , target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial infarcti

224 The incidence of major adverse cardiac events (MACE; the combined end point of

225 n (MI)/revascularization/stroke (i.e., major adverse cardiac events [MACE]) and secondary endpoints o

226 s associated with reduced incidence of major adverse cardiac events (MACEs) and cardiovascular (CV) r

227 The primary end points were major adverse cardiac events (MACEs) defined as cardiovascular

228 Evaluation for major adverse cardiac events (MACEs) occurred at 30 days (deat

229 Major adverse cardiac events (MACEs) were defined as late reva

230 according to their short-term risk for major adverse cardiac events (MACEs), but its effect on daily

231 l-cause mortality (ACM) and documented major adverse cardiac events (MACEs)-myocardial infarction, ho

232 Clinical outcomes in terms of major adverse cardiac events (major adverse cardiac events, a

233 he composite major adverse events (ie, major adverse cardiac events, major bleeding, or thromboemboli

234 ome (ACS), who have a low short-term risk of adverse cardiac events may be suitable for early dischar

235 The primary outcome was 30-day major adverse cardiac events (mortality, readmission for acute

236 diovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or

237 activity with prevalent CVD and future major adverse cardiac events (myocardial infarction, stroke, o

238 Patients in whom major adverse cardiac events occurred had significantly larger

239 Major adverse cardiac events occurred in 1.1% and 4.2% of ever

240 Major adverse cardiac events occurred in 173 diabetics (14.5%)

241 One or more adverse cardiac events occurred in 18%; congestive heart

242 After 5 years, major adverse cardiac events occurred in 31% of patients (154

243 0.76 to -0.21) and a decreased risk of major adverse cardiac events (odds ratio, 0.49; 95% CI, 0.25 t

244 ely followed up for 27+/-10 months for major adverse cardiac events of death, death or myocardial inf

245 findings do not directly contribute to major adverse cardiac event outcomes.

246 rates of recurrent mitral regurgitation and adverse cardiac events over time.

247 death and heart failure (P=0.004) and major adverse cardiac events (P=0.013).

248 nd vomiting on the basis of the potential of adverse cardiac events (prolongation of the QT interval

249 Overall, the 5-year major adverse cardiac event rate was 11.0%, without any scaffo

250 The 1-year adverse cardiac event rate was 16.4% in patients with in

251 m follow-up was 3.1 years, and overall major adverse cardiac event rate was 19.9% (death rate: 1.2%;

252 Two-year major adverse cardiac event rate was 6.8% without any scaffold

253 The 1-year major adverse cardiac event rate was increased among patients

254 The major adverse cardiac event rate was lower, too, in the allo g

255 ssociated with significantly increased major adverse cardiac events rate throughout 10 years of follo

256 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P=0.96)

257 Reduced adverse cardiac event rates are at least partially offse

258 Major adverse cardiac event rates at 2 years among those witho

259 higher in-hospital, 30-day, and 1-year major adverse cardiac event rates than patients without IPTE (

260 One- and 6-month major adverse cardiac event rates were low and similar in both

261 Major adverse cardiac event rates were similar (13.0% vs. 11.0

262 herapy resulted in similar reductions in net adverse cardiac event rates within the 300-mg (15.2% vs.

263 ith subsequent significantly increased major adverse cardiac event rates.

264 umen dimensions and low restenosis and major adverse cardiac event rates.

265 Target lesion revascularization and major adverse cardiac events rates during follow-up were highe

266 At 3 mo, 96 patients were free of major adverse cardiac events, repeat hospital chest pain evalu

267 nts were composite upper GI events and major adverse cardiac events, respectively.

268 For association with major adverse cardiac events, RevPD was the strongest multivar

269 o significant differences in composite major adverse cardiac event scores at each time point up to 48

270 h <50% diameter stenosis may carry a risk of adverse cardiac events similar to that in patients with

271 esel exhaust (DE) would increase the risk of adverse cardiac events such as arrhythmia and myocardial

272 sentation has an independent effect on major adverse cardiac events, suggesting that ISR remains a ha

273 OPCAB had lower risk-adjusted odds of major adverse cardiac events than their racial counterparts wh

274 eek mortality and 9-month incidence of major adverse cardiac events (the composite of death, Q-wave m

275 5% CI, 1.19-1.73) all predicted MACEs [major adverse cardiac events]." These ORs and 95% CIs should h

276 end points included clinical outcomes (major adverse cardiac events), use of healthcare resources, an

277 e index and a significant reduction in major adverse cardiac event was evident.

278 Overall occurrence of major adverse cardiac events was significantly less frequent i

279 The incidence of major adverse cardiac events was significantly lower in partic

280 At 30 days, the incidence of major adverse cardiac events was similar between the control a

281 The impact of ICR on major adverse cardiac events was similar regardless of chronic

282 spite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE

283 ratios (95% confidence intervals) for major adverse cardiac events were 0.77 (0.68-0.87), 0.82 (0.73

284 The 9-month rates of major adverse cardiac events were 12.1% and 11.2% at hospitals

285 Two-year major adverse cardiac events were 16.9% (retrospectively ident

286 The rates of major adverse cardiac events were 9.5% in hospitals without on

287 08 as measured by the VerifyNow assay; major adverse cardiac events were defined as the composite of

288 d long-term risk of SCAD recurrence or major adverse cardiac events were evaluated.

289 Major adverse cardiac events were numerically lower in the ato

290 ns, although significant reductions in major adverse cardiac events were present in all patient subgr

291 In-hospital major adverse cardiac events were significantly lower among pa

292 re-vascularized by CABG, mortality and major adverse cardiac events were significantly lower with a l

293 associated with lower risk for midterm major adverse cardiac events when used to supplement SITA or B

294 these patients (reduced mortality and major adverse cardiac events) with an increase in major bleedi

295 thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES implantat

296 The primary end point was death or major adverse cardiac events within 1 year after surgery.

297 inical end point was the occurrence of major adverse cardiac events within 1 year.

298 5% confidence interval, 3.6%-9.5%) had major adverse cardiac events within 30 days of randomization.

299 nts identified for early discharge had major adverse cardiac events within 30 days.

300 (ZES 17.0% versus EES 16.2%, P=0.61), major adverse cardiac events (ZES 21.9% versus EES 21.6%, P=0.